The germline variant rs4864950 T>A in the KDR gene increased the risk of composite toxicity (occurrence of any of hypertension, diarrhea and dermatological reactions) in patients treated with the VEGFR TKIs sorafenib and regorafenib (Quintanilha et al., 2022a). The gene discussed is KDR; the disease is hypertensive disorder.